A Five-miRNA Panel Identified From a Multicentric Case-control Study Serves as a Novel Diagnostic Tool for Ethnically Diverse Non-small-cell Lung Cancer Patients.
A Five-miRNA Panel Identified From a Multicentric Case-control Study Serves as a Novel Diagnostic Tool for Ethnically Diverse Non-small-cell Lung Cancer Patients.
复制标题
从多中心病例对照研究中鉴定出的五种 miRNA 组合可作为针对不同种族非小细胞肺癌患者的新型诊断工具。
DOI：
10.1016/j.ebiom.2015.07.034
复制
发表时间：
2015-10
期刊：
影响因子：
11.1
通讯作者：
Zhang CY
中科院分区：
文献类型：
--
作者：
Wang C;Ding M;Xia M;Chen S;Van Le A;Soto-Gil R;Shen Y;Wang N;Wang J;Gu W;Wang X;Zhang Y;Zen K;Chen X;Zhang C;Zhang CY
循环microRNAs(MiRNAs)是一种很有前景的癌症检测生物标志物。然而，缺乏对非小细胞肺癌(NSCLC)的多民族和多中心研究。我们招募了来自中国和美国的221例非小细胞肺癌患者、161例正常对照和56例良性结节。使用TaqMan低密度阵列进行miRNA的初步筛选，然后通过RT-qPCR进行个体确认。最后，我们进行了一项来自美国队列的盲法试验，以验证我们的发现。RT-qPCR证实，患者组miR-483-5p、miR-193a-3p、miR-25、miR-214和miR-7均显著高于对照组。两个确认集的ROC曲线下面积(AUC)分别为0.976(95%CI，0.939~1.0；P<0.0001)和0.823(95%CI，0.75~0.896；P<0.0001)。在盲法试验中，专家小组正确地将95%的非小细胞肺癌病例和84%的对照病例从美国队列中分类出来。最重要的是，该小组能够区分美国队列中AUC值为0.979(95%CI，0.959-1.0%)的非小细胞肺癌和良性结节，并能够正确预测中国和美国队列中I-II期肿瘤的86%和95%。这一血清miRNA板具有诊断种族多样化的NSCLC患者的潜力。进行了一项多种族、多中心的病例对照研究，以确定诊断非小细胞肺癌的血清miRNA特征。为准确诊断中美两国非小细胞肺癌患者，构建了一种基于5-miRNA的分类器。5-miRNA板可以准确检测非小细胞肺癌，特别是来自正常和良性结节受试者的I-II期病例。Wang等人。构建了一个基于5-miRNA的分类器，从多种族、多中心、病例对照研究中提供了在中国和美国患者中准确诊断非小细胞肺癌的可能性。更重要的是，5-miRNA小组能够准确检测非小细胞肺癌病例，特别是来自正常和良性结节受试者的I-II期病例。这些结果表明，5-miRNA标记可能是诊断不同种族NSCLC的一个有用的生物标志物，并有助于区分早期NSCLC与正常和良性结节患者，这可能有助于未来NSCLC患者的个性化治疗。
Circulating microRNAs (miRNAs) are promising biomarkers for cancer detection. However, multiethnic and multicentric studies of non-small-cell lung cancer (NSCLC) are lacking. We recruited 221 NSCLC patients, 161 controls and 56 benign nodules from both China and America. Initial miRNA screening was performed using the TaqMan Low Density Array followed by confirming individually by RT-qPCR in Chinese cohorts. Finally, we performed a blind trial from an American cohort to validate our findings. RT-qPCR confirmed that miR-483-5p, miR-193a-3p, miR-25, miR-214 and miR-7 were significantly elevated in patients compared to controls. The areas under the curve (AUCs) of the ROC curve of this five-serum miRNA panel were 0.976 (95% CI, 0.939–1.0; P < 0.0001) and 0.823 (95% CI, 0.75–0.896; P < 0.0001) for the two confirmation sets, respectively. In the blind trial, the panel correctly classified 95% NSCLC cases and 84% controls from the American cohort. Most importantly, the panel was capable of distinguishing NSCLC from benign nodules with an AUC of 0.979 (95% CI, 0.959–1.0) in the American cohort and allowed correct prediction of 86% and 95% stage I–II tumors in the Chinese and American cohorts, respectively. This serum miRNA panel holds the potential for diagnosing ethnically diverse NSCLC patients. A multiethnic, multicentric, case–control study was conducted to identify serum miRNA signature for diagnosing NSCLC. A five-miRNA-based classifier for accurate diagnosis of NSCLC among patients of Chinese and America was constructed. The five-miRNA panel allowed accurate detection of NSCLC especially stage I–II cases from normal and benign nodule subjects. Wang et al. constructed a five-miRNA-based classifier which provides the potential for accurate diagnosis of NSCLC among patients of Chinese and America from a multiethnic, multicentric, case–control study. More importantly, the five-miRNA panel allowed accurate detection of NSCLC cases especially stage I–II cases from normal and benign nodule subjects. These results suggest that the five-miRNA signature might be a useful biomarker for diagnosing NSCLC in ethnically diverse patients and help discriminate early stage NSCLC from normal and benign nodule subjects, which may benefit personalized therapy of NSCLC patients in the future.